FNY Investment Advisers’s Marker Therapeutics MRKR Stock Holding History

FNY Investment Advisers’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-600	Closed	-$16K	–	840
2021 Q2	$16K	Sell	600 -1,100	-65%	-$29K	0.01%	540
2021 Q1	$38K	Buy	+1,700	New	+$38.9K	0.01%	466
2020 Q2	–	Sell	-2,000	Closed	-$38K	–	526
2020 Q1	$38K	Sell	2,000 -1,533	-43%	-$39.1K	0.03%	243
2019 Q4	$101K	Buy	3,533 +327	+10%	+$11.9K	0.03%	362
2019 Q3	$163K	Buy	3,206 +718	+29%	+$42.4K	0.05%	216
2019 Q2	$197K	Sell	2,488 -760	-23%	-$45.1K	0.06%	162
2019 Q1	$214K	Buy	3,248 +2,433	+299%	+$142K	0.07%	165
2018 Q4	$45K	Buy	815 +459	+129%	+$33.5K	0.02%	249
2018 Q3	$32K	Buy	356 +106	+42%	+$9.1K	0.01%	410
2018 Q2	$23K	Buy	+250	New	+$12.7K	0.01%	349

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

FNY Investment Advisers's MRKR Position: Q3 2021 in Review

FNY Investment Advisers sold out of Marker Therapeutics (MRKR) in Q3 2021, closing a stake of 600 shares — an estimated $16K sold.

FNY Investment Advisers first reported a position in MRKR in Q2 2018 and held it in 10 quarters. The position peaked at $214K in Q1 2019. 63 funds tracked by Wall St. Rank hold MRKR as of Q3 2021.

FNY Investment Advisers reported no remaining Marker Therapeutics position as of Q3 2021 after selling out during the quarter.
FNY Investment Advisers sold 600 Marker Therapeutics shares in Q3 2021, an estimated $16K.
FNY Investment Advisers first reported a position in Marker Therapeutics in Q2 2018 and held it in 10 quarters.
FNY Investment Advisers's Marker Therapeutics position peaked at $214K in Q1 2019.
63 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2021.

Based on FNY Investment Advisers's 13F filing for Q3 2021, filed 13 Oct 2021.